<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02705040</url>
  </required_header>
  <id_info>
    <org_study_id>TMU-JIRB 201310015</org_study_id>
    <nct_id>NCT02705040</nct_id>
  </id_info>
  <brief_title>Roles of microRNAs in the Development of Osteoporosis in Men - Preliminary Study</brief_title>
  <official_title>Roles of microRNAs in the Development of Osteoporosis in Men - Preliminary Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taipei Medical University WanFang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taipei Medical University WanFang Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is aimed to evaluate the roles of specific miRNAs in osteoporosis in men.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the past, osteoporosis is usually viewed as a woman disease. However, men and women are
      shown to lose their bone mass at the same rate by more than 65 of age, and osteoporosis in
      men causes higher mortality in men than those in women. Thus, osteoporosis in men has
      recently aroused public attention. Androgen deficiency was the main cause leading to
      osteoporosis. Bone structure is maintained by a dynamic balance of osteoblast-mediated bone
      formation and osteoclast-mediated bone resorption. Androgens and androgen receptor (AR) play
      critical roles in regulation of bone formation and resorption. MicroRNAs (miRNAs) are
      non-coding small RNAs and participate in regulating activities of osteoblasts and osteoclasts
      by postranslationally targeting certain gene expressions. miR-133 and -135 can target BMP-2,
      Runx2, and Smad5 and then regulate osteoblast differentiation. Likewise, miR-141 and -200a
      negatively regulated osteoblast differentiation. Nevertheless, the functional roles of miRNAs
      in osteoporosis in men are still unknown. In addition, miRNA are stable and can be detected
      in the blood as novel biomarkers for certain diseases. A recent study analyzed the levels of
      miRNAs in circulating monocytes of 10 high and 10 low bone mineral density postmenopausal
      Caucasian women and found miR-133a is a potential biomarker for postmenopausal osteoporosis.
      In comparison, the roles of blood miRNAs in osteoporosis in men have not been evaluated.
      Therefore, this study is aimed to evaluate the roles of specific miRNAs in osteoporosis in
      men.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Bone mineral density</measure>
    <time_frame>30 minutes</time_frame>
    <description>T scale</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>Normal</arm_group_label>
    <description>bone mineral density T&gt;=-1.0</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Osteopenia</arm_group_label>
    <description>bone mineral density -1.0&gt;T&gt;=-2.5</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Osteoporosis</arm_group_label>
    <description>bone mineral density T&lt;-2.5</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Normal</intervention_name>
    <description>bone mineral density T&gt;=-1.0</description>
    <arm_group_label>Osteopenia</arm_group_label>
    <arm_group_label>Osteoporosis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Osteopenia</intervention_name>
    <description>bone mineral density -1.0&gt;T&gt;=-2.5</description>
    <arm_group_label>Normal</arm_group_label>
    <arm_group_label>Osteoporosis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Osteoporosis</intervention_name>
    <description>bone mineral density T&lt;-2.5</description>
    <arm_group_label>Normal</arm_group_label>
    <arm_group_label>Osteopenia</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma, urine
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The oriental men
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Twenty oriental men (mean age, 80 years; age range, 70-90 years).

          2. Candidates have no clinical evidence or history of focal lesions of the femur;
             previous hip surgery or irradiation; hip trauma; spinal trauma.

          3. Participants who have thoroughly understood and signed the consent form.

          4. Ten normal adult male (age range, 20-40 years).

        Exclusion Criteria:

          1. Participants with secondary causes of osteoporosis, such as thyroid, parathyroid
             disease, osteogenesis imperfect and osteomalacia.

          2. Participants with Paget's disease, serious liver disease, serious renal disease
             (indicated by a serum creatinine concentration of more than 1.6mg/dL).

          3. Participants who currently or have history of using steroids or hormone replacement
             therapy.

          4. Participants who fail to sign to the consent form.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ruei-Ming Chen, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Taipei Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ruei-Ming Chen, PhD</last_name>
    <phone>+886-27361661</phone>
    <phone_ext>3222</phone_ext>
    <email>rmchen@tmu.edu.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>Taipei Medical University Wanfang Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruei-Ming Chen, PhD</last_name>
      <phone>+886-27361661</phone>
      <phone_ext>3222</phone_ext>
      <email>rmchen@tmu.edu.tw</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 29, 2016</study_first_submitted>
  <study_first_submitted_qc>March 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 10, 2016</study_first_posted>
  <last_update_submitted>March 6, 2016</last_update_submitted>
  <last_update_submitted_qc>March 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 10, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>male osteoporosis</keyword>
  <keyword>miRNA</keyword>
  <keyword>biomarker</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

